CathVision raises venture funding for further development of its health products.

CathVision, a Copenhagen, Denmark-based company developing a electrophysiology (EP) recording system for treating cardiac arrhythmia, announced entering into a multi-million venture investment deal with Scandinavian-based investors VF Venture and Borean Innovation.

The investment will be used to further develop and market the company's products, by conducting clinical tests and going to the market.

CathVision, founded in 2013 and led by CEO Mads Emil Matthiesen, has developed a proprietary low-noise EP system that helps guide the medical professionals to the right spot for cardiac ablation.